Small synthetic molecule replacement for antibody

Indi Molecular has pioneered a novel approach to oncology therapeutics by developing synthetic small molecules that target overexpressed folate receptors in ovarian cancer and KRAS G12D expressing pancreatic cancers. Utilizing a unique platform known as Protein Catalyzed Capture (PCC), the company has created small synthetic peptide replacements for traditional antibody-based therapies. These PCC agents exhibit high specificity for their target proteins, with pico-molar to low nano-molar binding affinities, and demonstrate cooperative binding that enhances their effectiveness. The use of D-amino acids in their design ensures that these molecules are stable, water-soluble, and can be efficiently cleared by the kidneys.

The rapid development capabilities of Indi Molecular's technology allow for the transition from identifying a target epitope to achieving nanomolar binding affinity in just four weeks. This speed is complemented by the robust manufacturing process enabled by the fully synthetic nature of the peptides. Furthermore, the PCC agents have shown promising in vivo functional activity, indicating their potential to deliver therapeutic effects against both intracellular and extracellular targets. This innovative approach positions Indi Molecular at the forefront of targeted cancer therapy, offering a new avenue for treatment in challenging oncological conditions.

United States

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry.  Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology.

The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.

Indi Molecular

Company Details